Which Tests Help Clinicians to Better Personalise IVF Treatments?

What is an Anti-Müllerian Hormone (AMH) test?

The Access Anti-Müllerian hormone (AMH) Advanced from Beckman Coulter provides validated cut-offs for the assessment of ovarian reserve and ovarian response as an aid for women undergoing IVF. This new assay helps clinicians predict poor ovarian response in those who plan to undergo controlled ovarian stimulation as part of an in vitro fertilisation (IVF) protocol. The AMH Advanced assay is available in European countries that accept the CE marking. 

“With the new Access AMH Advanced assay, clinicians now have a tool to predict poor ovarian response so they can establish individualised treatment for ovarian stimulation in women undergoing an assisted reproductive technology programme,” said Kathleen Orland, Senior Vice President & General Manager of Clinical Chemistry Immunoassay at Beckman Coulter Diagnostics. 

The AMH Advanced assay allows clinicians to:
•    Determine a woman's ovarian reserve and make informed treatment decisions for women struggling with infertility, undergoing IVF, or planning pregnancies later in life
•    The test can be used for fertility purposes to determine ovarian status and use in IVF for controlled ovarian stimulation, but also for menopause evaluation and pathophysiology for polycystic ovary syndrome, granulosa cell tumours, intersex disorders/ambiguous genitalia differentiation, and precocious or delayed puberty.

How important is AMH testing?

AMH testing has become increasingly important in monitoring female reproductive health to help provide personalised guidance, predict ovarian response to IVF treatment, and avoid ovarian hyperstimulation. The Advanced AMH assay provides accurate and validated assay-specific cut-offs to guide clinical use. The assay also aids in establishing the individual daily dose of the human recombinant follicle-stimulating hormone rFSH (follitropin delta) marked by Ferring Pharmaceuticals in controlled ovarian stimulation for the development of multiple follicles in women undergoing in vitro fertilisation.

AMH is a widely accepted biomarker used to evaluate several clinical conditions, including infertility treatment, menopause evaluation, ovarian dysfunction (such as polycystic ovary syndrome), gonadotoxic cancer treatment and ovarian surgery.

“Beckman Coulter is the leading innovator in AMH testing, having pioneered the test over 20 years ago. Clinicians have continued to appreciate the utility of the test since, unlike other biomarkers, AMH has minimal variability throughout the menstrual cycle,” said Heather Read-Harper, Senior Marketing Manager for immunoassay and clinical chemistry at Beckman Coulter Diagnostics. “We continue on our innovator’s journey by delivering the only AMH assay on the market that provides its own validated cut-offs for ovarian response, while also assessing ovarian reserve.”

More information online